- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 87,800 | 29.05.24 08:20:01 | -1,060 | -1,19% | 87,800 | 88,200 | 87,800 | 88,860 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 888,200 | 29.05.24 08:34:17 | -13,000 | -1,44% | 888,000 | 898,800 | 888,200 | 901,200 |
